UPDATE: Sterne Agee Reiterates Buy Rating, Raises PT on Allscripts Healthcare Solutions

In a report published Monday, Sterne Agee Group reiterated its Buy rating on Allscripts Healthcare Solutions MDRX, and raised its price target from $13.50 to $15.00. Sterne Agee noted, “Our analysis suggests a $15-19 valuation range for MDRX shares should a go-private transaction be consummated by year-end. At the low end, this valuation range is 20% above today's closing price, while the top end implies 50% upside. As such, we have raised our price target to $15 per share from $13.50.” Allscripts Healthcare Solutions closed on Friday at $12.42.